Horizon Therapeutics (HZNP) | Stock Overview & Key Data
Horizon Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $116.30
High: $116.34
on June 20, 2025
52 Week Range
Low: $116.30
High: $116.34
on February 6, 2025
on February 6, 2025
All-Time High: $39.49 on July 20, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$26.6B
EPS
2.22
P/E Ratio (TTM)
61.86
Forward P/E
20.55
P/B Ratio
5.01
PEG Ratio
-16.29
Div. Yield
N/A
ROE
10.28%
Beta
N/A
Debt to Equity
0.48
Financial Highlights
Profitability
Gross Margin
76.72%
Operating Margin
16.83%
Profit Margin
74.64%
Returns and Earnings
Return on Assets (TTM)
5.72%
Return on Equity (TTM)
10.28%
EBITDA
$957.0M
Net Income (TTM)
$521.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$15.85
Quarterly Revenue Growth (YoY)
13.57%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Horizon Therapeutics HZNP | 26.63B Large-cap | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6.82% | 74.04% | 9.84% |
| Eli Lilly and LLY | 636.32B Mega-cap | 1.49% | -8.34% | -0.49% | -19.26% | -8.53% | -25.30% | 125.53% | 383.02% |
| Johnson & Johnson JNJ | 430.92B Mega-cap | 1.50% | 6.76% | 17.48% | 9.50% | 24.49% | 9.24% | 9.14% | 16.69% |
| Merck & Co MRK | 215.01B Mega-cap | 3.75% | 7.06% | 12.24% | -4.27% | -11.90% | -25.07% | -2.12% | 6.90% |
| Amgen AMGN | 159.23B Large-cap | -0.93% | -3.92% | 8.03% | -5.17% | 13.28% | -10.67% | 22.05% | 16.04% |
| Pfizer PFE | 146.35B Large-cap | 2.94% | 2.94% | 12.33% | -2.89% | -2.74% | -10.45% | -44.72% | -28.05% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
19M
Average 90-Day Volume
8M
Horizon Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Horizon Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HZNP's 52-week high and low?
- In the last 52 weeks, Horizon Therapeutics reached a high of $116.34 (on February 6, 2025) and a low of $116.30 (on February 6, 2025).
- What is the market cap and P/E ratio for HZNP?
- Curious about Horizon Therapeutics's size and valuation? Its market capitalization stands at 26.63B. When it comes to valuation, the P/E ratio (trailing twelve months) is 61.86, and the forward P/E (looking ahead) is 20.55.
- Does HZNP pay dividends? If so, what's the yield?
- As for dividends, Horizon Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Horizon Therapeutics's main competitors or similar companies to consider before investing?
When looking at Horizon Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY636.32B Healthcare Drug Manufacturers - General -25.30% 125.53% Johnson & Johnson
JNJ430.92B Healthcare Drug Manufacturers - General 9.24% 9.14% Merck & Co
MRK215.01B Healthcare Drug Manufacturers - General -25.07% -2.12% Amgen
AMGN159.23B Healthcare Drug Manufacturers - General -10.67% 22.05% Pfizer
PFE146.35B Healthcare Drug Manufacturers - General -10.45% -44.72% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Horizon Therapeutics Plc? (e.g., ROE, Debt/Equity)
- To get a sense of Horizon Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.28%, the Debt to Equity ratio from the most recent quarter is 0.48, and its Gross Profit Margin stands at 76.72%.
- What is the recent revenue and earnings growth for HZNP?
- Looking at Horizon Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.57%, and quarterly earnings saw a YoY growth of N/A.
- How much of HZNP stock is held by insiders and institutions?
- Wondering who owns Horizon Therapeutics stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.